



# Maximum Fair Price (MFP) Explanation for Farxiga

## Introduction

In August 2022, President Biden signed the Inflation Reduction Act of 2022 (IRA) (P.L. 117-169) into law. For the first time, the law provides Medicare with the ability to directly negotiate the prices of certain high expenditure, single source drugs without generic or biosimilar competition. On March 15, 2023, the Centers for Medicare & Medicaid Services (CMS) issued [initial guidance](#) for the Medicare Drug Price Negotiation Program (the “Negotiation Program”), including requests for public comment on key elements. On June 30, 2023, CMS issued [revised guidance](#) detailing the requirements and parameters of the Negotiation Program for the first cycle of negotiations.<sup>1</sup> CMS engaged in negotiations with participating manufacturers between October 1, 2023 and August 1, 2024. These negotiations resulted in agreements establishing prices (which the IRA refers to as “maximum fair prices” or “MFPs”) that will be effective beginning in 2026 (the first cycle of negotiations is referred to as negotiations for “initial price applicability year 2026” because any agreed-upon prices will be effective in 2026). CMS published the agreed-upon MFPs on August 15, 2024.

The MFP explanation for Farxiga for the agreed-upon MFP that resulted from the negotiations for initial price applicability year 2026 with AstraZeneca AB, the manufacturer of Farxiga (the “Primary Manufacturer”), provides information about the negotiations for Farxiga. This information includes CMS’ perspective on the data considered that had the greatest impact in CMS’ determination of offers and consideration of counteroffers during the negotiation process through which the parties reached agreement on an MFP.<sup>2</sup> In some respects, the Primary Manufacturer had a different perspective on the relevant data. The parties to the negotiation had productive exchanges during the negotiation meetings described below in which they discussed their respective views, and these exchanges resulted in the exchange of offer(s) and counteroffer(s) among the parties and, ultimately, an agreed-upon MFP for Farxiga.

On the basis of the factors described below and the related considerations and evidence, CMS negotiated with the Primary Manufacturer in good faith and consistent with the requirements of the law on behalf of people with Medicare and the Medicare program. Throughout the negotiation process and in accordance with the IRA, CMS’ goal was to achieve agreement with the Primary Manufacturer on the lowest possible MFP for Farxiga that would be consistent with the process defined in the IRA for these price negotiations. CMS believes that the agreed-upon MFP achieves this aim. The negotiation process

---

<sup>1</sup> The [Medicare Drug Price Negotiation Program: Revised Guidance, Implementation of Sections 1191 – 1198 of the Social Security Act for Initial Price Applicability Year 2026](#), is referred to throughout this document as the revised guidance.

<sup>2</sup> Section 1195(a)(2) of the Social Security Act (the “Act”) requires CMS to publish an explanation for the MFP with respect to the factors as applied under section 1194(e) for each selected drug. The MFP explanation is discussed in section 60.6.1 of the [revised guidance](#).

ended in both parties agreeing to an MFP of \$178.50 for Farxiga by the conclusion of the negotiation period on August 1, 2024.<sup>3</sup> The agreed-upon MFP is set to take effect on January 1, 2026.

The MFP explanation contains the following components:

- MFP Explanation Narrative for Farxiga
  - Summary of the Negotiation Process
  - Indications for Farxiga
  - Factors Applied
  - Manufacturer-Specific Data
  - Evidence about Farxiga and Therapeutic Alternatives to Farxiga
    - Therapeutic Alternatives
    - Outcomes and Additional Considerations
  - Citations to Data Reviewed during the Negotiation Process for Farxiga
- Redacted Negotiation Meeting Summaries for Farxiga
- Redacted Data Submitted by the Primary Manufacturer and Other Interested Parties for Farxiga

## MFP Explanation Narrative for Farxiga

### Summary of the Negotiation Process

CMS followed the negotiation process laid out in the IRA and in the revised guidance. On August 29, 2023, CMS announced the 10 selected drugs for the first cycle of negotiations, which included Farxiga. The Primary Manufacturers of the selected drugs signed agreements to participate in the Negotiation Program by the deadline in the IRA of October 1, 2023 and submitted information on the selected drugs by the deadline in the IRA of October 2, 2023.

CMS collected relevant data from numerous sources, such as written submissions from the Primary Manufacturers and other interested parties in response to an information collection request issued for the Negotiation Program (referred to as the “Negotiation Program information collection request” throughout this document), feedback from patient-focused listening sessions, meetings between CMS and the Primary Manufacturers to discuss the information submitted, and CMS’ literature review.<sup>4</sup>

Using the information collected, CMS then developed initial offers for the selected drugs, which were based on the factors outlined in the IRA for CMS’ determination of offers and which CMS developed in accordance with the process described in the revised guidance.<sup>5</sup> As required by the IRA, CMS’ initial offers each included a concise justification on the range of evidence and other information within the negotiation factors that CMS found compelling during the development of the initial offer. The Primary Manufacturers each responded by declining CMS’ initial offer and providing a written counteroffer and justification for such offer, including considerations based on the negotiation factors.

---

<sup>3</sup> The MFP is expressed as the price per 30-days equivalent supply. See section 60.1 of the [revised guidance](#) and the [Negotiated Prices for Initial Price Applicability Year 2026 Fact Sheet](#) for additional information.

<sup>4</sup> The Negotiation Program information collection request is available on the Office of Management and Budget’s (OMB’s) website at the following link: [https://www.reginfo.gov/public/do/PRAViewICR?ref\\_nbr=202306-0938-013](https://www.reginfo.gov/public/do/PRAViewICR?ref_nbr=202306-0938-013).

<sup>5</sup> Section 1194(e) of the Act requires CMS to consider certain data as the basis for all offers and counteroffers in the negotiation. These data, which are referred to in this document as the “negotiation factors,” are discussed in more detail later in this document. More information on the negotiation factors is also available in sections 50, 60.3 and 60.4 of the [revised guidance](#). CMS’ process for developing the initial offers is described in section 60.3 of the revised guidance.

CMS considered each counteroffer proposed by the Primary Manufacturers and declined each counteroffer. CMS and each Primary Manufacturer then held three negotiation meetings. These meetings included extensive discussion of the negotiation factors, including any new information consistent with the factors that may have become available about the selected drugs or therapeutic alternatives, CMS' initial offer and the Primary Manufacturer's written counteroffer, and, in some cases, additional proposals for an MFP.

Across the first cycle of negotiations for all ten selected drugs, more than 50 revised offers or counteroffers were proposed by CMS or a Primary Manufacturer, not including the ten initial offers CMS made and the ten written counteroffers provided by Primary Manufacturers. During the negotiation meetings, CMS revised its initial offer for each selected drug upwards at least once in response to the discussions with the Primary Manufacturer. While many of the details of the negotiations are confidential between CMS and each Primary Manufacturer, the frequency of revised offers and counteroffers in the first cycle of negotiations indicates the robustness of the negotiations that occurred for each of the ten drugs. CMS' approach to its negotiations with each Primary Manufacturer turned on the particular details relevant to each selected drug and was sensitive to the issues raised during the course of CMS' conversations with the Primary Manufacturer. CMS anticipates this drug-specific approach will continue to inform CMS' negotiations with participating manufacturers in future cycles of negotiation.

Overall, in six of ten negotiations CMS moved more than the Primary Manufacturer during the meetings and for the final offer (if applicable) prior to reaching agreement, and in four of ten negotiations the Primary Manufacturer moved more than CMS prior to reaching agreement. For five of the selected drugs, this process of exchanging revised offers and counteroffers resulted in CMS and the Primary Manufacturer reaching an agreement on a negotiated price for the selected drug in association with a negotiation meeting. In four of these cases, CMS accepted a revised counteroffer proposed by the Primary Manufacturer. For the remaining five selected drugs, CMS sent a written final offer to the Primary Manufacturer, consistent with the process described in the revised guidance, and in each instance, the Primary Manufacturer accepted CMS' offer on or before the statutory deadline. Throughout the negotiation process, CMS and the Primary Manufacturers exchanged perspectives about a range of topics related to the negotiation factors, and while the parties did not always agree, CMS appreciated the Primary Manufacturers' engagement.

A detailed timeline of the negotiation process for Farxiga is below.

- August 29, 2023: CMS announced the 10 selected drugs for initial price applicability year 2026
- October 1, 2023: Deadline for the Primary Manufacturer to sign an agreement to participate in the Negotiation Program
- October 2, 2023: Deadline for the Primary Manufacturer and the public to submit information related to Farxiga in response to the Negotiation Program information collection request
- October 25, 2023: CMS met with the Primary Manufacturer regarding its response to the Negotiation Program information collection request
- November 2, 2023: CMS held a patient-focused listening session for Farxiga
- February 1, 2024: CMS provided the Primary Manufacturer with CMS' initial offer
- March 1, 2024: The Primary Manufacturer rejected CMS' initial offer and provided CMS with a counteroffer
- March 29, 2024: CMS rejected the Primary Manufacturer's counteroffer and invited the Primary Manufacturer to a negotiation meeting
- April 23, 2024: CMS and the Primary Manufacturer met for the first negotiation meeting

- May 22, 2024: CMS and the Primary Manufacturer met for the second negotiation meeting
- June 28, 2024: CMS and the Primary Manufacturer met for the third negotiation meeting
- August 1, 2024: The negotiation period ended
- August 15, 2024: MFP of \$178.50 was published

## Indications for Farxiga

Farxiga is a sodium-glucose cotransporter 2 inhibitor that works by helping the kidneys remove glucose (sugar) and sodium from the bloodstream. Farxiga is used to treat conditions like type 2 diabetes mellitus (T2DM), chronic kidney disease (CKD), and heart failure (HF). It may be combined with other medications or lifestyle modifications, like diet and exercise, to treat these conditions.<sup>6</sup>

For Farxiga, CMS included the following indications in its assessment<sup>7</sup>:

Description of indication	Terminology used in this document
<ul style="list-style-type: none"> <li>• To reduce the risk of sustained eGFR decline, end stage kidney disease, cardiovascular (CV) death, and hospitalization for heart failure (HF) in adults with chronic kidney disease at risk of progression.</li> </ul>	CKD
<ul style="list-style-type: none"> <li>• To reduce the risk of CV death, hospitalization for HF, and urgent HF visit in adults with HF.</li> </ul>	HF
<ul style="list-style-type: none"> <li>• To reduce the risk of hospitalization for HF in adults with type 2 diabetes mellitus and either established CV disease or multiple CV risk factors.</li> </ul>	T2DM and CVD or multiple CV risk factors
<ul style="list-style-type: none"> <li>• As an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus.</li> </ul>	T2DM

*Table 1.* CKD = chronic kidney disease; CVD = cardiovascular disease; T2DM = type 2 diabetes mellitus. For purposes of CMS' consideration of indications for Farxiga, CMS grouped certain indications using the terminology as shown in this table. CMS' use of the terms listed here does not alter the FDA-approved indications for Farxiga.

<sup>6</sup> To compose this brief description, CMS used various sources, including MedlinePlus, a free online health information resource for patients and the general public. MedlinePlus is a service of the National Library of Medicine (NLM), a part of the U.S. National Institutes of Health (NIH). For more information about any drugs or conditions mentioned in this document, MedlinePlus can be accessed at: <https://medlineplus.gov/>.

<sup>7</sup> CMS' process for identifying indications for a selected drug was to identify the FDA-approved indication(s) not otherwise excluded from coverage or otherwise restricted under section 1860D-2(e)(2) of the Act, using prescribing information approved by the FDA for the selected drug, in accordance with section 1194(e)(2)(B) of the Act. CMS considered off-label use when identifying indications if such use was included in nationally recognized, evidence-based guidelines and recognized in CMS-approved Part D compendia. CMS included indications that met these criteria during the negotiation period. Indications newly approved by FDA or included in nationally recognized, evidence-based guidelines and recognized in CMS-approved Part D compendia after the end of the negotiation period were not included.

## Factors Applied

Consistent with the IRA, CMS considered certain negotiation factors as the basis for determining all offers and counteroffers during the negotiation process.

The following negotiation factors are referred to in this document as “manufacturer-specific data”<sup>8</sup>:

- Research and development (R&D) costs of the Primary Manufacturer for Farxiga and the extent to which the Primary Manufacturer has recouped R&D costs;
- Current unit costs of production and distribution of Farxiga;
- Prior Federal financial support for novel therapeutic discovery and development with respect to Farxiga;
- Data on pending and approved patent applications, exclusivities recognized by the FDA, and applications and approvals for New Drug Applications and Biologics License Applications for Farxiga;<sup>9</sup> and
- Market data and revenue and sales volume data for Farxiga in the United States (U.S.).

The following negotiation factors are referred to in this document as “evidence about Farxiga and therapeutic alternatives to Farxiga”<sup>10</sup>:

- The extent to which Farxiga represents a therapeutic advance as compared to existing therapeutic alternatives and the costs of such existing therapeutic alternatives;
- Prescribing information approved by the FDA for Farxiga and therapeutic alternatives to Farxiga;
- Comparative effectiveness of Farxiga and therapeutic alternatives to Farxiga, taking into consideration the effects of Farxiga and therapeutic alternatives to Farxiga on specific populations, such as individuals with disabilities, the elderly, the terminally ill, children, and other patient populations; and
- The extent to which Farxiga and therapeutic alternatives to Farxiga address unmet medical needs for a condition for which treatment or diagnosis is not addressed adequately by available therapy.

The below sections describe how CMS considered and applied these factors during the negotiation process. CMS considered these factors, taking into account all data in totality during the negotiation process.

CMS and the Primary Manufacturer did not always agree on the information presented below, and the Primary Manufacturer was not restricted to consideration of these factors during the negotiation process but was free to discuss any topics with CMS it deemed relevant to its consideration of offer(s) and counteroffer(s) for Farxiga.

---

<sup>8</sup> These factors are listed at section 1194(e)(1) of the Act.

<sup>9</sup> New Drug Applications are approved under section 505(c) of the Federal Food, Drug, and Cosmetic Act and Biologics License Applications are approved under section 351(a) of the Public Health Service Act.

<sup>10</sup> These factors are listed at section 1194(e)(2) of the Act. In accordance with section 1194(e)(2) and section 1182(e) of Title XI of the Act, CMS did not use evidence from comparative clinical effectiveness research in a manner that treats extending the life of an individual who is elderly, disabled, or terminally ill as of lower value than extending the life of an individual who is younger, non-disabled, or not terminally ill, and, consistent with section 1182(e) of Title XI of the Act, did not use quality adjusted life years (QALYs).

## Manufacturer-Specific Data

CMS considered the information submitted by the Primary Manufacturer related to the manufacturer-specific data factors. These factors include R&D costs and the extent to which the Primary Manufacturer has recouped R&D costs, current unit costs of production and distribution, prior Federal financial support, data on pending and approved patents and exclusivities recognized by the FDA, and market data, including revenue and sales volume data for the drug in the United States. CMS considered these factors in totality, as part of its application of the negotiation factors during the negotiation process.

The Primary Manufacturer provided CMS with information for each of these factors in response to the Negotiation Program information collection request.<sup>11</sup> For R&D costs, CMS requested information separated into various categories of costs related to R&D, including acquisition costs, pre-clinical research costs, post-Investigational New Drug costs, costs of failed or abandoned products related to Farxiga, and other allowable direct costs. CMS also requested the global and U.S. total lifetime net revenue for Farxiga to provide insight into the extent to which the Primary Manufacturer has recouped R&D costs. CMS requested current average unit costs of production for Farxiga and current average unit costs of distribution for Farxiga separately, as well as a description of the methodology the Primary Manufacturer used to estimate such costs. For information related to prior Federal financial support, CMS requested the total amount of Federal financial support received, as well as a breakdown by various types of financial support, like tax credits and National Institutes of Health funding. CMS requested information on patents, both expired and unexpired, issued by the U.S. Patent and Trademark Office, patent applications, regulatory exclusivity periods, and active and pending FDA applications and approvals. For market data, CMS requested information about the prices for Farxiga and volume dispensed for other payers in the U.S. market, including commercial payers (e.g., the U.S. commercial average net price), Medicaid (Medicaid Best Price), and other Federal payers (the Federal supply schedule price and the Big Four price).

Throughout the negotiation process, CMS holistically considered the information submitted by the Primary Manufacturer related to the manufacturer-specific data negotiation factors for the purpose of negotiating an MFP for Farxiga. For example, CMS applied information on prices for Farxiga available to other payers in the U.S. market and how they compared to any offers or counteroffers when considering whether a potential price was consistent with CMS' aim to arrive at an agreement on the lowest possible MFP. The totality of CMS' application of these factors, in conjunction with application of the factors described below, informed CMS' negotiation of the MFP with the Primary Manufacturer.

## Evidence about Farxiga and Therapeutic Alternatives to Farxiga

CMS considered information related to the negotiation factors regarding evidence about Farxiga and therapeutic alternatives to Farxiga. CMS' holistic consideration of clinical benefit included evidence from sources such as: pivotal clinical trials, pre-specified subgroup analyses, clinical practice guidelines, expert consensus statements, comparative clinical evidence, published literature reviews, real-world evidence, and FDA prescription drug labeling, among others. CMS evaluated the evidence based on a variety of considerations, including relevance and credibility, giving priority to well-designed and well-conducted

---

<sup>11</sup> In accordance with the revised guidance, CMS treats R&D costs and the extent to which they are recouped, unit costs of production and distribution, pending patent applications, and market, revenue, and sales volume data as proprietary, unless the information that is provided to CMS is already publicly available. For more information, see section 40.2.1 of the [revised guidance](#).

studies, as stated in the revised guidance.<sup>12</sup> In general, CMS prioritized direct comparative evidence (e.g., head-to-head randomized controlled trials) when available. CMS also reviewed mixed and/or indirect treatment comparisons (e.g., network meta-analyses) when available and real-world evidence (e.g., observational studies) when available as part of its holistic assessment of comparative evidence.

In addition to information from the Primary Manufacturer, CMS received information from the public, including from patients during the patient-focused listening session held by CMS on November 2, 2023.<sup>13</sup> Patient input was important to CMS' consideration of the evidence about Farxiga and therapeutic alternatives to Farxiga, including to help identify outcomes of interest for patients and to understand additional considerations such as the drug's impact on patients' day-to-day lives. For example, speakers at the patient-focused listening session discussed the impact that slowing progression of cardiovascular disease can have on patients' quality of life. This was one consideration among the many that informed CMS' understanding of the factors regarding evidence about Farxiga and its therapeutic alternatives. Throughout all of the patient-focused listening sessions for the first cycle of negotiations, speakers provided insight on the importance of affordability and access, which provided CMS helpful context for the speakers' described experiences.

## Therapeutic Alternatives

The IRA directs CMS to compare Farxiga to therapeutic alternatives in its determination of offers and consideration of counteroffers for Farxiga.<sup>14</sup> In the revised guidance, CMS defines a therapeutic alternative for the first cycle of negotiations as a pharmaceutical product that is clinically comparable to the selected drug.<sup>15</sup>

Importantly, use of the term “therapeutic alternative” in this MFP explanation is limited to the purposes and definition outlined in the IRA and the revised guidance. Use of this term does not suggest that CMS believes such drugs are interchangeable or otherwise universally appropriate to prescribe for an individual in place of Farxiga or that these are the only pharmaceutical treatments that might be used by a person with one of the indications treated by Farxiga. CMS trusts that patients and health care providers will continue to choose the therapy that best suits a given patient's needs based on the patient's health, history, experience, and preferences, the provider's expertise, FDA-approved prescribing information, and relevant clinical guidelines, as applicable.

During the negotiation process, CMS identified therapeutic alternatives to Farxiga based on a holistic consideration of the available evidence from a range of sources. In addition to the sources listed above, such as data submitted by the Primary Manufacturer and the public and widely accepted clinical

---

<sup>12</sup> In section 50.2 of the [revised guidance](#), CMS stated, “When reviewing the literature from the public and manufacturer submissions as well as literature from CMS' review, CMS will consider the source, rigor of the study methodology, current relevance to the selected drug and its therapeutic alternative(s), whether the study has been through peer review, study limitations, degree of certainty of conclusions, risk of bias, study time horizons, generalizability, study population, and relevance to the negotiation factors listed in section 1194(e)(2) of the Act to ensure the integrity of the contributing data within the negotiation process. CMS will prioritize research, including both observational research and research based on randomized samples, that is methodologically rigorous, appropriately powered (i.e., has sufficient sample size) to answer the primary question of the research, and structured to avoid potential false positive findings due to multiple subgroup analyses.”

<sup>13</sup> The redacted transcript for this patient-focused listening session is available at the following link: <https://www.cms.gov/files/document/farxiga-transcript-110223.pdf>.

<sup>14</sup> See section 1194(e)(2) of the Act and sections 50, 60.3 and 60.4 of the [revised guidance](#) for additional information.

<sup>15</sup> This definition appears in Appendix C of the [revised guidance](#).



guidelines, other examples of data sources used include the following: drug classification systems commonly used in the public and commercial sector for formulary development, indications included in CMS-approved Part D compendia, and drug or drug class reviews.

The following table lists the therapeutic alternatives, among all clinically comparable alternatives that CMS reviewed, which were particularly relevant to CMS' consideration, due to guideline recommendations, utilization in the Medicare population, and other considerations.

Indication	Therapeutic Alternatives
CKD	<ul style="list-style-type: none"> <li>• Empagliflozin</li> </ul>
HF	<ul style="list-style-type: none"> <li>• Empagliflozin</li> </ul>
T2DM and CVD or multiple CV risk factors	<ul style="list-style-type: none"> <li>• Canagliflozin</li> <li>• Dulaglutide</li> <li>• Empagliflozin</li> <li>• Liraglutide</li> <li>• Semaglutide</li> </ul>
T2DM	<ul style="list-style-type: none"> <li>• Canagliflozin</li> <li>• Dulaglutide</li> <li>• Empagliflozin</li> <li>• Glimepiride</li> <li>• Glipizide</li> <li>• Metformin</li> <li>• Pioglitazone</li> <li>• Semaglutide</li> <li>• Sitagliptin</li> </ul>

*Table 2.* CKD = chronic kidney disease; CV = cardiovascular; CVD = cardiovascular disease; HF = heart failure; T2DM = type 2 diabetes mellitus. Use of the term “therapeutic alternative” in this MFP explanation is limited to the purposes and definition outlined in the IRA and the revised guidance. Use of this term does not suggest that CMS believes such drugs are interchangeable or otherwise universally appropriate to prescribe for an individual in place of Farxiga or that these are the only pharmaceutical treatments that might be used by a person with one of the indications treated by Farxiga. CMS trusts that patients and health care providers will continue to choose the therapy that best suits a given patient’s needs based on the patient’s health, history, experience, and preferences, the provider’s expertise, FDA-approved prescribing information, and relevant clinical guidelines, as applicable.

CMS considered utilization for Farxiga and its therapeutic alternatives by indication as one part of its application of the negotiation factors.

## Outcomes and Additional Considerations

Outcomes are measurable effects or impacts of a treatment or intervention. Outcomes can be used to measure differences in the safety or effectiveness of different treatments. Patient-centered outcomes are outcomes identified by patients that are important to how they feel, function, or survive. To consider comparative effectiveness between Farxiga and therapeutic alternatives to Farxiga, CMS identified clinically relevant and patient-centered outcomes of interest from the body of available literature to evaluate for each indication of Farxiga. CMS then identified evidence comparing Farxiga to therapeutic alternatives based on these outcomes. The following table includes a non-exhaustive list of outcomes that were of interest to CMS in its consideration of Farxiga:



Indication	Effectiveness Outcomes	Safety Outcomes
CKD	<ul style="list-style-type: none"> <li>Progression of kidney disease (e.g., renal composite outcome)</li> <li>Cardiovascular death</li> <li>Hospitalization for HF</li> </ul>	<ul style="list-style-type: none"> <li>Serious adverse events</li> <li>Tolerability (e.g., discontinuation due to adverse events)</li> <li>Urinary tract infection</li> <li>Genital mycotic infection</li> </ul>
HF	<ul style="list-style-type: none"> <li>Hospitalization for HF</li> <li>Cardiovascular death</li> <li>Patient-reported health status (e.g., KCCQ)</li> </ul>	<ul style="list-style-type: none"> <li>Serious adverse events</li> <li>Tolerability (e.g., discontinuation due to adverse events)</li> <li>Urinary tract infection</li> <li>Genital mycotic infection</li> </ul>
T2DM and CVD or multiple CV risk factors	<ul style="list-style-type: none"> <li>Cardiovascular death</li> <li>Hospitalization for HF</li> <li>Stroke</li> <li>Myocardial infarction</li> <li>Glycemic control (e.g., hemoglobin A1c)</li> </ul>	<ul style="list-style-type: none"> <li>Serious adverse events</li> <li>Tolerability (e.g., discontinuation due to adverse events)</li> <li>Urinary tract infection</li> <li>Genital mycotic infection</li> </ul>
T2DM	<ul style="list-style-type: none"> <li>Glycemic control (e.g., hemoglobin A1c)</li> </ul>	<ul style="list-style-type: none"> <li>Serious adverse events</li> <li>Tolerability (e.g., discontinuation due to adverse events)</li> <li>Urinary tract infection</li> <li>Genital mycotic infection</li> <li>Hypoglycemia</li> </ul>

*Table 3.* CKD = chronic kidney disease; CV = cardiovascular; CVD = cardiovascular disease; HF = heart failure; KCCQ = Kansas City Cardiomyopathy Questionnaire; T2DM = type 2 diabetes mellitus. Outcomes identified in this table were of interest to CMS in its evaluation of Farxiga. Evidence to support an assessment may not have been available for every outcome of interest.

Outcomes, like those listed above, were identified as being of interest to CMS based on their importance to patients and their ability to measure how effective and safe a drug is when used to treat these indications. For example, major adverse cardiovascular events, like myocardial infarction (i.e., heart attack), stroke, hospitalization for HF, and death from cardiovascular causes, are key outcomes that are often used to evaluate the effectiveness of treatments for patients with T2DM and CVD or multiple CV risk factors. In addition, across indications, the risk of serious adverse events and tolerability, or the degree to which patients can tolerate adverse events associated with taking a drug, are outcomes that reflect important safety considerations when evaluating drugs for these indications.

Additionally, CMS considered the extent to which Farxiga represents a therapeutic advance as compared to existing therapeutic alternatives, and the extent to which Farxiga and its therapeutic alternatives address an unmet medical need. CMS also evaluated access, equity, and health outcomes for specific populations (including individuals with disabilities, the elderly, individuals who are terminally ill, children, and other patient populations).

For the purpose of negotiating the MFP for Farxiga, CMS holistically considered the negotiation factors regarding evidence about Farxiga and its therapeutic alternatives, including consideration of the clinical benefit of Farxiga in the context of its therapeutic alternatives. For example, CMS applied its understanding of the comparative effectiveness of Farxiga and its therapeutic alternatives for each of the identified indications, including for the management of glycemic control in patients with T2DM and reduction of cardiovascular risk for patients with T2DM and CVD or multiple CV risk factors, when negotiating with the Primary Manufacturer. CMS' holistic assessment was informed by additional contextual considerations, including use in patients with certain common co-occurring conditions treated by Farxiga, complexity of treatment regimens, FDA safety labeling, and patients' preferences regarding treatment.

Throughout the negotiation process, including the development of the initial offer and in the consideration of any offers and counteroffers, CMS applied these and other factors regarding evidence about Farxiga and therapeutic alternatives. The totality of CMS' application of these factors, in conjunction with application of the manufacturer-submitted data negotiation factors described above, informed CMS' negotiation of the MFP with the Primary Manufacturer.

## Citations to Data Reviewed during the Negotiation Process for Farxiga

CMS provides below a list of citations representative of evidence that CMS reviewed during the negotiation process, including citations provided by the Primary Manufacturer and the public in response to the Negotiation Program information collection request, those included in CMS' initial offer concise justification, and other citations which were considered during the evaluation of the Primary Manufacturer's counteroffer and during negotiation meetings.

Consistent with the IRA and section 1182(e) of Title XI of the Act, CMS did not use evidence from comparative clinical effectiveness research in a manner that treats extending the life of an individual who is elderly, disabled, or terminally ill as of lower value than extending the life of an individual who is younger, nondisabled, or not terminally ill, and, consistent with section 1182(e) of Title XI of the Act, did not use quality adjusted life years (QALYs). Inclusion on this list of a citation that contains such evidence does not mean that CMS used such evidence in the course of the negotiation.

This list is intended to provide insight into the range of evidence that various parties, including CMS and the Primary Manufacturer, identified as being relevant to the negotiation. This list does not represent the totality of evidence that CMS reviewed and considered as part of its holistic consideration of the negotiation factors in the determination of any offers and consideration of any counteroffers.

1. Adams J, Mosler C. Safety and efficacy considerations amongst the elderly population in the updated treatment of heart failure: a review. *Expert Rev Cardiovasc Ther.* 2022;20(7):529-41. Epub 20220708. doi: 10.1080/14779072.2022.2098118. PubMed PMID: 35786091.
2. Agency for Healthcare Research and Quality (AHRQ). Advancing Patient-Centered Care for People Living with Multiple Chronic Conditions [Internet]. Maryland: U.S. Department of Health and Human Services [cited 2023 Oct 2]. Available from: <https://www.ahrq.gov/patient-safety/settings/long-term-care/resource/multichronic/mcc.html>.
3. Aimo A, Pateras K, Stamatelopoulos K, Bayes-Genis A, Lombardi CM, Passino C, et al. Relative Efficacy of Sacubitril-Valsartan, Vericiguat, and SGLT2 Inhibitors in Heart Failure with Reduced Ejection Fraction: a Systematic Review and Network Meta-Analysis. *Cardiovasc Drugs Ther.* 2021;35(5):1067-76. Epub 20201019. doi: 10.1007/s10557-020-07099-2. PubMed PMID: 33074526.
4. Alicic RZ, Neumiller JJ, Johnson EJ, Dieter B, Tuttle KR. Sodium-Glucose Cotransporter 2 Inhibition and Diabetic Kidney Disease. *Diabetes.* 2019;68(2):248-57. doi: 10.2337/dbi18-0007. PubMed PMID: 30665953.
5. American Diabetes Association Professional Practice Committee. 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2024. *Diabetes Care.* 2024;47(Suppl 1):S179-S218. doi: 10.2337/dc24-S010. PubMed PMID: 38078592; PubMed Central PMCID: PMC10725811.
6. American Diabetes Association Professional Practice Committee. 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes-2024. *Diabetes Care.* 2024;47(Suppl 1):S219-S30. doi: 10.2337/dc24-S011. PubMed PMID: 38078574; PubMed Central PMCID: PMC10725805.
7. American Diabetes Association Professional Practice Committee. 13. Older Adults: Standards of Care in Diabetes-2024. *Diabetes Care.* 2024;47(Suppl 1):S244-S57. doi: 10.2337/dc24-S013. PubMed PMID: 38078580; PubMed Central PMCID: PMC10725804.

8. American Diabetes Association Professional Practice Committee. 14. Children and Adolescents: Standards of Care in Diabetes-2024. *Diabetes Care*. 2024;47(Suppl 1):S258-S81. doi: 10.2337/dc24-S014. PubMed PMID: 38078582; PubMed Central PMCID: PMC10725814.
9. American Diabetes Association Professional Practice Committee. 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes-2024. *Diabetes Care*. 2024;47(Suppl 1):S20-S42. doi: 10.2337/dc24-S002. PubMed PMID: 38078589; PubMed Central PMCID: PMC10725812.
10. American Diabetes Association Professional Practice Committee. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2024. *Diabetes Care*. 2024;47(Suppl 1):S158-S78. doi: 10.2337/dc24-S009. PubMed PMID: 38078590; PubMed Central PMCID: PMC10725810.
11. Arnold SV, Kosiborod M, Wang J, Fenici P, Gannedahl G, LoCasale RJ. Burden of cardio-renal-metabolic conditions in adults with type 2 diabetes within the Diabetes Collaborative Registry. *Diabetes Obes Metab*. 2018;20(8):2000-3. Epub 20180419. doi: 10.1111/dom.13303. PubMed PMID: 29577540.
12. Arnott C, Li Q, Kang A, Neuen BL, Bompont S, Lam CSP, et al. Sodium-Glucose Cotransporter 2 Inhibition for the Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis. *J Am Heart Assoc*. 2020;9(3):e014908. Epub 20200129. doi: 10.1161/JAHA.119.014908. PubMed PMID: 31992158; PubMed Central PMCID: PMC7033896.
13. AstraZeneca. Farxiga (dapagliflozin) [package insert]. U.S. Food and Drug Administration. Revised 2024 Jun. Available from: [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2024/202293s031lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/202293s031lbl.pdf).
14. AstraZeneca. Farxiga (dapagliflozin) [package insert]. U.S. Food and Drug Administration. Revised 2023 Sep. Available from: [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2023/202293s030lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202293s030lbl.pdf).
15. Background Document: Dapagliflozin. Bristol-Myers Squibb Company, AstraZeneca LP; 2013 Nov 12. Report No. BMS-512148. Available from: <https://wayback.archive-it.org/7993/20170405215747/https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM378079.pdf>.
16. Bahrami H, Kronmal R, Bluemke DA, Olson J, Shea S, Liu K, et al. Differences in the incidence of congestive heart failure by ethnicity: the multi-ethnic study of atherosclerosis. *Arch Intern Med*. 2008;168(19):2138-45. doi: 10.1001/archinte.168.19.2138. PubMed PMID: 18955644; PubMed Central PMCID: PMC3038918.
17. Bailey CJ, Gross JL, Pieters A, Bastien A, List JF. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. *Lancet*. 2010;375(9733):2223-33. doi: 10.1016/S0140-6736(10)60407-2. PubMed PMID: 20609968.
18. Bayer HealthCare Pharmaceuticals Inc. Kerendia (finerenone) [package insert]. U.S. Food and Drug Administration. Revised 2021 Jul. Available from: [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2021/215341s000lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215341s000lbl.pdf).
19. Belasco A, Barbosa D, Bettencourt AR, Diccini S, Sesso R. Quality of life of family caregivers of elderly patients on hemodialysis and peritoneal dialysis. *Am J Kidney Dis*. 2006;48(6):955-63. doi: 10.1053/j.ajkd.2006.08.017. PubMed PMID: 17162150.
20. Belasco AG, Sesso R. Burden and quality of life of caregivers for hemodialysis patients. *Am J Kidney Dis*. 2002;39(4):805-12. doi: 10.1053/ajkd.2002.32001. PubMed PMID: 11920347.

21. Berg DD, Jhund PS, Docherty KF, Murphy SA, Verma S, Inzucchi SE, et al. Time to Clinical Benefit of Dapagliflozin and Significance of Prior Heart Failure Hospitalization in Patients With Heart Failure With Reduced Ejection Fraction. *JAMA Cardiol.* 2021;6(5):499-507. doi: 10.1001/jamacardio.2020.7585. PubMed PMID: 33595593; PubMed Central PMCID: PMC7890451.
22. Bhatt DL, Szarek M, Steg PG, Cannon CP, Leiter LA, McGuire DK, et al. Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. *N Engl J Med.* 2021;384(2):117-28. Epub 20201116. doi: 10.1056/NEJMoa2030183. PubMed PMID: 33200892.
23. Birkeland KI, Bodegard J, Eriksson JW, Norhammar A, Haller H, Linssen GCM, et al. Heart failure and chronic kidney disease manifestation and mortality risk associations in type 2 diabetes: A large multinational cohort study. *Diabetes Obes Metab.* 2020;22(9):1607-18. Epub 20200603. doi: 10.1111/dom.14074. PubMed PMID: 32363737; PubMed Central PMCID: PMC7496468.
24. Blonde L, Umpierrez GE, Reddy SS, McGill JB, Berga SL, Bush M, et al. American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. *Endocr Pract.* 2022;28(10):923-1049. Epub 20220811. doi: 10.1016/j.eprac.2022.08.002. PubMed PMID: 35963508; PubMed Central PMCID: PMC10200071.
25. Boehringer Ingelheim Pharmaceuticals, Inc. Jardiance (empagliflozin) [package insert]. U.S. Food and Drug Administration. Revised 2023 Sep. Available from: [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2023/204629s040lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/204629s040lbl.pdf).
26. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. *N Engl J Med.* 2001;345(12):861-9. doi: 10.1056/NEJMoa011161. PubMed PMID: 11565518.
27. Bristol-Myers Squibb. Glucophage, Glucophage XR (metformin hydrochloride) [package insert]. U.S. Food and Drug Administration. Revised 2018 May. Available from: [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2018/020357s034,021202s018lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020357s034,021202s018lbl.pdf).
28. Butler J, Packer M, Filippatos G, Ferreira JP, Zeller C, Schnee J, et al. Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction. *Eur Heart J.* 2022;43(5):416-26. doi: 10.1093/eurheartj/ehab798. PubMed PMID: 34878502; PubMed Central PMCID: PMC8825259.
29. Butt JH, Dewan P, Merkely B, Belohlavek J, Drozd J, Kitakaze M, et al. Efficacy and Safety of Dapagliflozin According to Frailty in Heart Failure With Reduced Ejection Fraction : A Post Hoc Analysis of the DAPA-HF Trial. *Ann Intern Med.* 2022;175(6):820-30. Epub 20220426. doi: 10.7326/M21-4776. PubMed PMID: 35467935.
30. Butt JH, Docherty KF, Claggett BL, Desai AS, Fang JC, Petersson M, et al. Dapagliflozin in Black and White Patients With Heart Failure Across the Ejection Fraction Spectrum. *JACC Heart Fail.* 2023;11(4):375-88. Epub 20230201. doi: 10.1016/j.jchf.2022.11.014. PubMed PMID: 36881399.
31. Caceres V. Heart Disease Statistics and Risk Factors [Internet]. Verywell Health; 2024 Feb 1. Available from: <https://www.verywellhealth.com/heart-disease-statistics-5198489>.
32. Cahn A, Mosenzon O, Wiviott SD, Rozenberg A, Yanuv I, Goodrich EL, et al. Efficacy and Safety of Dapagliflozin in the Elderly: Analysis From the DECLARE-TIMI 58 Study. *Diabetes Care.* 2020;43(2):468-75. Epub 20191216. doi: 10.2337/dc19-1476. PubMed PMID: 31843945.

33. Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research. Guidance for Industry: E7 Studies in Support of Special Populations: Geriatrics. Questions and Answers. U.S. Food and Drug Administration; 2012 Feb. Available from: <https://www.fda.gov/files/drugs/published/E7-Studies-in-Support-of-Special-Populations--Geriatrics--Questions-and-Answers.pdf>.
34. Chen HB, Meng RS, Yang YL, Yu TH. The risk of all-cause death with dapagliflozin versus placebo: a systematic review and meta-analysis of phase III randomized controlled trials. *Expert Opin Drug Saf.* 2023;22(2):133-40. Epub 20230226. doi: 10.1080/14740338.2023.2182290. PubMed PMID: 36803188.
35. Chen HB, Yang YL, Meng RS, Liu XW. Indirect comparison of SGLT2 inhibitors in patients with established heart failure: evidence based on Bayesian methods. *ESC Heart Fail.* 2023;10(2):1231-41. Epub 20230126. doi: 10.1002/ehf2.14297. PubMed PMID: 36702979; PubMed Central PMCID: PMC10053258.
36. Chen JY, Pan HC, Shiao CC, Chuang MH, See CY, Yeh TH, et al. Impact of SGLT2 inhibitors on patient outcomes: a network meta-analysis. *Cardiovasc Diabetol.* 2023;22(1):290. Epub 20231027. doi: 10.1186/s12933-023-02035-8. PubMed PMID: 37891550; PubMed Central PMCID: PMC10612254.
37. Chen X, Wang J, Lin Y, Yao K, Xie Y, Zhou T. Cardiovascular outcomes and safety of SGLT2 inhibitors in chronic kidney disease patients. *Front Endocrinol (Lausanne).* 2023;14:1236404. Epub 20231116. doi: 10.3389/fendo.2023.1236404. PubMed PMID: 38047108; PubMed Central PMCID: PMC10690412.
38. CMS Office of Minority Health. Health Disparities Among Aged ESRD Beneficiaries, 2014. Centers for Medicare and Medicaid Services. Available from: <https://www.cms.gov/about-cms/agency-information/omh/downloads/esrd-infographic.pdf>.
39. Connelly KA, Bhatt DL, Verma S. Can We DECLARE a Victory against Cardio-Renal Disease in Diabetes? *Cell Metab.* 2018;28(6):813-5. doi: 10.1016/j.cmet.2018.11.010. PubMed PMID: 30517896.
40. Considering Clinical, Real-World, and Unpublished Evidence [Internet]. Institute for Clinical and Economic Review (ICER) [cited 2023 Sep 11]. Available from: <https://icer.org/our-approach/methods-process/considering-clinical-real-world-and-unpublished-evidence/>.
41. Coverage with Evidence Development (PROPOSED). Centers for Medicare and Medicaid Services; 2023 Jun 22. Report Available from: <https://www.cms.gov/medicare-coverage-database/view/medicare-coverage-document.aspx?mcdid=35>.
42. Dapagliflozin for Treating Chronic Kidney Disease: Technology Appraisal Guidance. National Institute for Health and Care Excellence (NICE); 2022 Mar 9. Report No. TA775. Available from: <https://www.nice.org.uk/guidance/ta775/resources/dapagliflozin-for-treating-chronic-kidney-disease-pdf-82611498049477>.
43. Davies MJ, Aroda VR, Collins BS, Gabbay RA, Green J, Maruthur NM, et al. Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetes Care.* 2022;45(11):2753-86. doi: 10.2337/dci22-0034. PubMed PMID: 36148880; PubMed Central PMCID: PMC10008140.
44. de Boer IH, Khunti K, Sadusky T, Tuttle KR, Neumiller JJ, Rhee CM, et al. Diabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). *Diabetes Care.* 2022;45(12):3075-90. doi: 10.2337/dci22-0027. PubMed PMID: 36189689; PubMed Central PMCID: PMC9870667.

45. de Zeeuw D. The future of Diabetic Kidney Disease management: reducing the unmet need. *J Nephrol.* 2020;33(6):1163-9. Epub 20200804. doi: 10.1007/s40620-020-00820-2. PubMed PMID: 32749580; PubMed Central PMCID: PMC7701076.
46. Delanaye P, Scheen AJ. Preventing and treating kidney disease in patients with type 2 diabetes. *Expert Opin Pharmacother.* 2019;20(3):277-94. Epub 20181203. doi: 10.1080/14656566.2018.1551362. PubMed PMID: 30462565.
47. Diabetes Occurrence, Costs, and Access to Care among Medicare Beneficiaries Aged 65 Years and Over. Centers for Medicare and Medicaid Services; 2017. Available from: [https://www.cms.gov/Research-Statistics-Data-and-Systems/Research/MCBS/Data-Briefs-Items/Diabetes\\_DataBrief\\_2017](https://www.cms.gov/Research-Statistics-Data-and-Systems/Research/MCBS/Data-Briefs-Items/Diabetes_DataBrief_2017).
48. Docherty KF, Bayes-Genis A, Butler J, Coats AJS, Drazner MH, Joyce E, et al. The four pillars of HFrEF therapy: is it time to treat heart failure regardless of ejection fraction? *Eur Heart J Suppl.* 2022;24(Suppl L):L10-L9. Epub 20221219. doi: 10.1093/eurheartjsupp/suac113. PubMed PMID: 36545228; PubMed Central PMCID: PMC9762881.
49. Docherty KF, Jhund PS, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA, et al. Effects of dapagliflozin in DAPA-HF according to background heart failure therapy. *Eur Heart J.* 2020;41(25):2379-92. doi: 10.1093/eurheartj/ehaa183. PubMed PMID: 32221582; PubMed Central PMCID: PMC7327533.
50. Docherty KF, Ogunniyi MO, Anand IS, Desai AS, Diez M, Howlett JG, et al. Efficacy of Dapagliflozin in Black Versus White Patients With Heart Failure and Reduced Ejection Fraction. *JACC Heart Fail.* 2022;10(1):52-64. Epub 20211110. doi: 10.1016/j.jchf.2021.08.006. PubMed PMID: 34969498.
51. Duan XY, Liu SY, Yin DG. Comparative efficacy of 5 sodium glucose cotransporter 2 inhibitor and 7 glucagon-like peptide 1 receptor agonists interventions on cardiorenal outcomes in type 2 diabetes patients: A network meta-analysis based on cardiovascular or renal outcome trials. *Medicine (Baltimore).* 2021;100(30):e26431. doi: 10.1097/MD.00000000000026431. PubMed PMID: 34397684; PubMed Central PMCID: PMC8322563.
52. Eli Lilly and Company. Mounjaro (tirzepatide) [package insert]. U.S. Food and Drug Administration. Revised 2022 May. Available from: [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2022/215866s000lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215866s000lbl.pdf).
53. Eli Lilly and Company. Trulicity (dulaglutide) [package insert]. U.S. Food and Drug Administration. Revised 2022 Jun. Available from: [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2022/125469s046s052lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125469s046s052lbl.pdf).
54. ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, et al. 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2023. *Diabetes Care.* 2023;46(Suppl 1):S158-S90. doi: 10.2337/dc23-S010. PubMed PMID: 36507632; PubMed Central PMCID: PMC9810475.
55. ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, et al. 13. Older Adults: Standards of Care in Diabetes-2023. *Diabetes Care.* 2023;46(Suppl 1):S216-S29. doi: 10.2337/dc23-S013. PubMed PMID: 36507638; PubMed Central PMCID: PMC9810468.
56. ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, et al. 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes-2023. *Diabetes Care.* 2023;46(Suppl 1):S191-S202. doi: 10.2337/dc23-S011. PubMed PMID: 36507634; PubMed Central PMCID: PMC9810467.
57. ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, et al. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2023. *Diabetes Care.* 2023;46(Suppl 1):S140-S57. doi: 10.2337/dc23-S009. PubMed PMID: 36507650; PubMed Central PMCID: PMC9810476.



58. Essien UR, Tang Y, Figueroa JF, Litam TMA, Tang F, Jones PG, et al. Diabetes Care Among Older Adults Enrolled in Medicare Advantage Versus Traditional Medicare Fee-For-Service Plans: The Diabetes Collaborative Registry. *Diabetes Care*. 2022;45(7):1549-57. doi: 10.2337/dc21-1178. PubMed PMID: 35796766; PubMed Central PMCID: PMC9577184.
59. Evans M, Morgan AR, Davies S, Beba H, Strain WD. The role of sodium-glucose co-transporter-2 inhibitors in frail older adults with or without type 2 diabetes mellitus. *Age Ageing*. 2022;51(10). doi: 10.1093/ageing/afac201. PubMed PMID: 36201329; PubMed Central PMCID: PMC9536439.
60. Farxiga Approved in the US for the Treatment of Chronic Kidney Disease in Patients at Risk of Progression with and without Type-2 Diabetes [Internet]. AstraZeneca; 2021 Apr 30 [cited 2023 Oct 2]. Available from: <https://www.astrazeneca.com/media-centre/press-releases/2021/farxiga-approved-in-the-us-for-ckd.html#>.
61. Farxiga granted Breakthrough Therapy Designation in US for chronic kidney disease [Internet]. AstraZeneca; 2020 [cited 2023 Oct 2]. Available from: <https://www.astrazeneca.com/media-centre/press-releases/2020/farxiga-granted-breakthrough-therapy-designation-in-us-for-chronic-kidney-disease.html#>.
62. FDA Approves Treatment for Chronic Kidney Disease [Internet]. U.S. Food and Drug Administration; 2021 Apr 30 [cited 2023 Oct 2]. Available from: <https://www.fda.gov/news-events/press-announcements/fda-approves-treatment-chronic-kidney-disease>.
63. Feng X, Astell-Burt T. Impact of a type 2 diabetes diagnosis on mental health, quality of life, and social contacts: a longitudinal study. *BMJ Open Diabetes Res Care*. 2017;5(1):e000198. Epub 20170216. doi: 10.1136/bmjdr-2016-000198. PubMed PMID: 28243446; PubMed Central PMCID: PMC5316913.
64. Ferdinand KC, Yadav K, Nasser SA, Clayton-Jeter HD, Lewin J, Cryer DR, et al. Disparities in hypertension and cardiovascular disease in blacks: The critical role of medication adherence. *J Clin Hypertens (Greenwich)*. 2017;19(10):1015-24. Epub 20170830. doi: 10.1111/jch.13089. PubMed PMID: 28856834; PubMed Central PMCID: PMC5638710.
65. Ferdinand KC. Improving Care for African-American Heart Failure Patients. *US Cardiology* 2006;3(1):86–9. doi.org/10.15420/usc.2006.3.1.86
66. Fioretto P, Mansfield TA, Ptaszynska A, Yavin Y, Johnsson E, Parikh S. Long-Term Safety of Dapagliflozin in Older Patients with Type 2 Diabetes Mellitus: A Pooled Analysis of Phase IIb/III Studies. *Drugs Aging*. 2016;33(7):511-22. doi: 10.1007/s40266-016-0382-1. PubMed PMID: 27357173; PubMed Central PMCID: PMC4937081.
67. Fitch K, Pelizzari P, Pyenson B. The high cost of heart failure for the Medicare population: An actuarial cost analysis. Milliman, Inc.; 2015 Feb 4. Available from: <https://us.milliman.com/en/insight/the-high-cost-of-heart-failure-for-the-medicarepopulation-an-actuarial-cost-analysis>.
68. Ghosal S, Ghosal S, Ghosal A. The Renal Composite Benefit of Sodium Glucose Co-Transporter 2 Inhibitors Should Ideally Be Assessed Based on a Standardised Definition: A Meta-Analysis of Randomised Controlled Trials. *J Clin Med*. 2023;12(20). Epub 20231011. doi: 10.3390/jcm12206462. PubMed PMID: 37892600; PubMed Central PMCID: PMC10607004.
69. Giugliano D, Longo M, Maiorino MI, Bellastella G, Chiodini P, Solerte SB, et al. Efficacy of SGLT-2 inhibitors in older adults with diabetes: Systematic review with meta-analysis of cardiovascular outcome trials. *Diabetes Res Clin Pract*. 2020;162:108114. Epub 20200309. doi: 10.1016/j.diabres.2020.108114. PubMed PMID: 32165164.
70. Giugliano D, Longo M, Signoriello S, Maiorino MI, Solerte B, Chiodini P, et al. The effect of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors on cardiorenal outcomes: a

- network meta-analysis of 23 CVOTs. *Cardiovasc Diabetol.* 2022;21(1):42. Epub 20220316. doi: 10.1186/s12933-022-01474-z. PubMed PMID: 35296336; PubMed Central PMCID: PMC8925229.
71. Golestaneh L, Alvarez PJ, Reaven NL, Funk SE, McGaughey KJ, Romero A, et al. All-cause costs increase exponentially with increased chronic kidney disease stage. *Am J Manag Care.* 2017;23(10 Suppl):S163-S72. PubMed PMID: 28978205.
  72. Gonzalez J, Bates BA, Setoguchi S, Gerhard T, Dave CV. Cardiovascular outcomes with SGLT2 inhibitors versus DPP4 inhibitors and GLP-1 receptor agonists in patients with heart failure with reduced and preserved ejection fraction. *Cardiovasc Diabetol.* 2023;22(1):54. Epub 20230310. doi: 10.1186/s12933-023-01784-w. PubMed PMID: 36899387; PubMed Central PMCID: PMC9999503.
  73. Hammerman A, Azuri J, Aboalhasan E, Arbel R. Dapagliflozin Versus Sacubitril-Valsartan to Improve Outcomes of Patients with Reduced Ejection Fraction and Diabetes Mellitus. *Am J Cardiovasc Drugs.* 2022;22(3):325-31. Epub 20211021. doi: 10.1007/s40256-021-00506-5. PubMed PMID: 34671945.
  74. Heerspink HJL, Kosiborod M, Inzucchi SE, Cherney DZI. Renoprotective effects of sodium-glucose cotransporter-2 inhibitors. *Kidney Int.* 2018;94(1):26-39. Epub 20180505. doi: 10.1016/j.kint.2017.12.027. PubMed PMID: 29735306.
  75. Heerspink HJL, Stefansson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, et al. Dapagliflozin in Patients with Chronic Kidney Disease. *N Engl J Med.* 2020;383(15):1436-46. Epub 20200924. doi: 10.1056/NEJMoa2024816. PubMed PMID: 32970396.
  76. Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *J Am Coll Cardiol.* 2022;79(17):e263-e421. Epub 20220401. doi: 10.1016/j.jacc.2021.12.012. PubMed PMID: 35379503.
  77. Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *Circulation.* 2022;145(18):e876-e94. Epub 20220401. doi: 10.1161/CIR.0000000000001062. PubMed PMID: 35363500.
  78. Herrington WG, Staplin N, Wanner C, Green JB, Hauske SJ, Emberson JR, et al. Empagliflozin in Patients with Chronic Kidney Disease. *N Engl J Med.* 2023;388(2):117-27. Epub 20221104. doi: 10.1056/NEJMoa2204233. PubMed PMID: 36331190; PubMed Central PMCID: PMC7614055.
  79. Huang H, Bell KF, Gani R, Tugwell CW, Eudicone JM, Krukas-Hampel MR. A retrospective real-world study of dapagliflozin versus other oral antidiabetic drugs added to metformin in patients with type 2 diabetes. *Am J Manag Care.* 2018;24(8 Suppl):S132-S7. PubMed PMID: 29693359.
  80. Hussein H, Zaccardi F, Khunti K, Davies MJ, Patsko E, Dhalwani NN, et al. Efficacy and tolerability of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: A systematic review and network meta-analysis. *Diabetes Obes Metab.* 2020;22(7):1035-46. Epub 20200318. doi: 10.1111/dom.14008. PubMed PMID: 32077218.
  81. Inzucchi SE, Claggett BL, Vaduganathan M, Desai AS, Jhund PS, de Boer RA, et al. Efficacy and safety of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction by baseline glycaemic status (DELIVER): a subgroup analysis from an international, multicentre, double-blind, randomised, placebo-controlled trial. *Lancet*

- Diabetes Endocrinol. 2022;10(12):869-81. Epub 20221110. doi: 10.1016/S2213-8587(22)00308-4. PubMed PMID: 36372069.
82. Jabbour S, Seufert J, Scheen A, Bailey CJ, Karup C, Langkilde AM. Dapagliflozin in patients with type 2 diabetes mellitus: A pooled analysis of safety data from phase IIb/III clinical trials. *Diabetes Obes Metab.* 2018;20(3):620-8. Epub 20171026. doi: 10.1111/dom.13124. PubMed PMID: 28950419; PubMed Central PMCID: PMC5836959.
  83. Janssen Pharmaceuticals, Inc. Invokana (canagliflozin) [package insert]. U.S. Food and Drug Administration. Revised 2023 Jul. Available from: [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2023/204042s040lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/204042s040lbl.pdf).
  84. Jhund PS, Kondo T, Butt JH, Docherty KF, Claggett BL, Desai AS, et al. Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER. *Nat Med.* 2022;28(9):1956-64. Epub 20220827. doi: 10.1038/s41591-022-01971-4. PubMed PMID: 36030328; PubMed Central PMCID: PMC9499855.
  85. Kamalesh M, Cleophas TJ. Heart failure due to systolic dysfunction and mortality in diabetes: pooled analysis of 39,505 subjects. *J Card Fail.* 2009;15(4):305-9. Epub 20081223. doi: 10.1016/j.cardfail.2008.11.006. PubMed PMID: 19398078.
  86. Kandelaki K, Marrone G, Lundborg CS, Schmidt I, Björkman I. Patient-centredness as a quality domain in Swedish healthcare: results from the first national surveys in different Swedish healthcare settings. *BMJ Open.* 2016;6(1):e009056. Epub 20160108. doi: 10.1136/bmjopen-2015-009056. PubMed PMID: 26747031; PubMed Central PMCID: PMC4716147.
  87. Kasichayanula S, Liu X, Pe Benito M, Yao M, Pfister M, LaCreta FP, et al. The influence of kidney function on dapagliflozin exposure, metabolism and pharmacodynamics in healthy subjects and in patients with type 2 diabetes mellitus. *Br J Clin Pharmacol.* 2013;76(3):432-44. doi: 10.1111/bcp.12056. PubMed PMID: 23210765; PubMed Central PMCID: PMC3769670.
  88. KDIGO 2023 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease: Public Review Draft. Kidney Disease Improving Global Outcomes (KDIGO); 2023 Jul. Available from: [https://web.archive.org/web/20231109104442/https://kdigo.org/wp-content/uploads/2017/02/KDIGO-2023-CKD-Guideline-Public-Review-Draft\\_5-July-2023.pdf](https://web.archive.org/web/20231109104442/https://kdigo.org/wp-content/uploads/2017/02/KDIGO-2023-CKD-Guideline-Public-Review-Draft_5-July-2023.pdf).
  89. Kidney Care Choices (KCC) Model [Internet]. Maryland: Centers for Medicare & Medicaid Services; 2019 Dec 4 [cited 2023 Oct 25]. Available from: <https://www.cms.gov/newsroom/fact-sheets/kidney-care-choices-kcc-model>.
  90. Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. *Kidney Int.* 2022;102(5S):S1-S127. doi: 10.1016/j.kint.2022.06.008. PubMed PMID: 36272764.
  91. Kilgore M, Patel HK, Kielhorn A, Maya JF, Sharma P. Economic burden of hospitalizations of Medicare beneficiaries with heart failure. *Risk Manag Healthc Policy.* 2017;10:63-70. Epub 20170510. doi: 10.2147/RMHP.S130341. PubMed PMID: 28546776; PubMed Central PMCID: PMC5436769.
  92. Kittleson MM, Panjath GS, Amancherla K, Davis LL, Deswal A, Dixon DL, et al. 2023 ACC Expert Consensus Decision Pathway on Management of Heart Failure With Preserved Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee. *J Am Coll Cardiol.* 2023;81(18):1835-78. Epub 20230419. doi: 10.1016/j.jacc.2023.03.393. PubMed PMID: 37137593.
  93. Kondo T, McMurray JJV. Re-emergence of heart failure with a normal ejection fraction? *Eur Heart J.* 2022;43(5):427-9. doi: 10.1093/eurheartj/ehab828. PubMed PMID: 34878520.

94. Kosiborod MN, Esterline R, Furtado RHM, Oscarsson J, Gasparyan SB, Koch GG, et al. Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Diabetes Endocrinol.* 2021;9(9):586-94. Epub 20210721. doi: 10.1016/S2213-8587(21)00180-7. PubMed PMID: 34302745; PubMed Central PMCID: PMC8294807.
95. Lawson CA, Seidu S, Zaccardi F, McCann G, Kadam UT, Davies MJ, et al. Outcome trends in people with heart failure, type 2 diabetes mellitus and chronic kidney disease in the UK over twenty years. *EClinicalMedicine.* 2021;32:100739. Epub 20210204. doi: 10.1016/j.eclinm.2021.100739. PubMed PMID: 33688855; PubMed Central PMCID: PMC7910705.
96. Lenti MV, Cococcia S, Ghorayeb J, Di Sabatino A, Selinger CP. Stigmatisation and resilience in inflammatory bowel disease. *Intern Emerg Med.* 2020;15(2):211-23. Epub 20191231. doi: 10.1007/s11739-019-02268-0. PubMed PMID: 31893346; PubMed Central PMCID: PMC7054377.
97. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. *N Engl J Med.* 2001;345(12):851-60. doi: 10.1056/NEJMoa011303. PubMed PMID: 11565517.
98. Lewsey SC, Breathett K. Racial and ethnic disparities in heart failure: current state and future directions. *Curr Opin Cardiol.* 2021;36(3):320-8. doi: 10.1097/HCO.0000000000000855. PubMed PMID: 33741769; PubMed Central PMCID: PMC8130651.
99. Lexicon. Inpefa (sotagliflozin) [package insert]. U.S. Food and Drug Administration. Revised 2023 May. Available from: [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2023/216203s000lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216203s000lbl.pdf).
100. List JF, Woo V, Morales E, Tang W, Fiedorek FT. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. *Diabetes Care.* 2009;32(4):650-7. Epub 20081229. doi: 10.2337/dc08-1863. PubMed PMID: 19114612; PubMed Central PMCID: PMC2660449.
101. Liu Y, An C, Liu P, Yang F, Zhao Q. Comparative safety of sodium-glucose co-transporter 2 inhibitors in elderly patients with type 2 diabetes mellitus and diabetic kidney disease: a systematic review and meta-analysis. *Ren Fail.* 2023;45(1):2217287. doi: 10.1080/0886022X.2023.2217287. PubMed PMID: 37246403; PubMed Central PMCID: PMC10228313.
102. Madero M. KDIGO 2023 CKD Guideline: Delaying CKD Progression and Complications: What's New?. *Kidney Disease Improving Global Outcomes*; Jun 2023. Available from: <https://kdigo.org/conferences/era-2023-ckd-guideline-draft-preview>.
103. Martinez FA, Serenelli M, Nicolau JC, Petrie MC, Chiang CE, Tereshchenko S, et al. Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age: Insights From DAPA-HF. *Circulation.* 2020;141(2):100-11. Epub 20191117. doi: 10.1161/CIRCULATIONAHA.119.044133. PubMed PMID: 31736328.
104. McCullough PA, Mehta HS, Barker CM, Houten JV, Mollenkopf S, Gunnarsson C, et al. Healthcare utilization and guideline-directed medical therapy in heart failure patients with reduced ejection fraction. *J Comp Eff Res.* 2021;10(14):1055-63. Epub 20210706. doi: 10.2217/cer-2021-0118. PubMed PMID: 34225473.
105. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Bohm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. *Eur Heart J.* 2021;42(36):3599-726. doi: 10.1093/eurheartj/ehab368. PubMed PMID: 34447992.
106. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Bohm M, et al. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic

- heart failure. *Eur Heart J*. 2023;44(37):3627-39. doi: 10.1093/eurheartj/ehad195. PubMed PMID: 37622666.
107. McEwan P, Boyce R, Sanchez JG, Sjoström CD, Stefansson B, Nolan S, et al. Extrapolated longer-term effects of the DAPA-CKD trial: a modelling analysis. *Nephrol Dial Transplant*. 2023;38(5):1260-70. doi: 10.1093/ndt/gfac280. PubMed PMID: 36301617; PubMed Central PMCID: PMC10157747.
108. McEwan P, Darlington O, Boyce R, Heerspink HJL, Wheeler DC, Garcia Sanchez J. Estimating the Impact of Delayed Disease Progression and Cardiovascular Event Incidence Associated with Dapagliflozin Based on the Results of Dapa-CKD. *Journal of Managed Care & Specialty Pharmacy*. 2021;27(4-a Suppl):S1-S152. doi: 10.18553/jmcp.2021.27.4-a.s1.
109. McEwan P, Morgan AR, Boyce R, Green N, Song B, Huang J, et al. Cardiorenal disease in the United States: Future health care burden and potential impact of novel therapies. *J Manag Care Spec Pharm*. 2022;28(4):415-24. Epub 20220112. doi: 10.18553/jmcp.2022.21385. PubMed PMID: 35016548.
110. McMurray JJV, Docherty KF. Insights into foundational therapies for heart failure with reduced ejection fraction. *Clin Cardiol*. 2022;45 Suppl 1(Suppl 1):S26-S30. doi: 10.1002/clc.23847. PubMed PMID: 35789017; PubMed Central PMCID: PMC9254667.
111. McMurray JJV, Solomon SD, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. *N Engl J Med*. 2019;381(21):1995-2008. Epub 20190919. doi: 10.1056/NEJMoa1911303. PubMed PMID: 31535829.
112. Merck Sharp & Dohme Corp. Januvia (sitagliptin) [package insert]. U.S. Food and Drug Administration. Revised 2022 Jun. Available from: [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2022/021995s050lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021995s050lbl.pdf).
113. Merck Sharp & Dohme LLC. Steglatro (ertugliflozin) [package insert]. U.S. Food and Drug Administration. Revised 2022 Oct. Available from: [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2022/209803s006lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209803s006lbl.pdf).
114. Mottl AK, Alicic R, Argyropoulos C, Brosius FC, Mauer M, Molitch M, et al. KDOQI US Commentary on the KDIGO 2020 Clinical Practice Guideline for Diabetes Management in CKD. *Am J Kidney Dis*. 2022;79(4):457-79. Epub 20220207. doi: 10.1053/j.ajkd.2021.09.010. PubMed PMID: 35144840; PubMed Central PMCID: PMC9740752.
115. National Institute of Diabetes and Digestive and Kidney Diseases. Kidney Disease Statistics for the United States [Internet]. National Institutes of Health; 2023 May [cited 2023 Oct 2]. Available from: <https://www.niddk.nih.gov/health-information/health-statistics/kidney-disease?dkrd=/health-information/kidney-disease/race-ethnicity>.
116. National Institute of Diabetes and Digestive and Kidney Diseases. Causes of Chronic Kidney Disease [Internet]. National Institutes of Health; 2016 Oct [cited 2023 Oct 2]. Available from: <https://www.niddk.nih.gov/health-information/kidney-disease/chronic-kidney-disease-ckd/causes>.
117. National Institute of Diabetes and Digestive and Kidney Diseases. Overview of the Immune System. National Institutes of Health; 2022. Available from: <https://usrds-adr.niddk.nih.gov/2022/chronic-kidney-disease/1-ckd-in-the-general-population>.
118. National Institute of Diabetes and Digestive and Kidney Diseases. United States Renal Data System: 2022 Annual Data Report. National Institutes of Health; 2022. Available from: <https://usrds-adr.niddk.nih.gov/2022>.
119. Ndumele CE, Neeland IJ, Tuttle KR, Chow SL, Mathew RO, Khan SS, et al. A Synopsis of the Evidence for the Science and Clinical Management of Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Scientific Statement From the American Heart Association. *Circulation*.

- 2023;148(20):1636-64. Epub 20231009. doi: 10.1161/CIR.0000000000001186. PubMed PMID: 37807920.
120. Neuen BL, Young T, Heerspink HJL, Neal B, Perkovic V, Billot L, et al. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. *Lancet Diabetes Endocrinol.* 2019;7(11):845-54. Epub 20190905. doi: 10.1016/S2213-8587(19)30256-6. PubMed PMID: 31495651.
  121. Nichols GA, Qiao Q, Linden S, Kraus BJ. Medical Costs of Chronic Kidney Disease and Type 2 Diabetes Among Newly Diagnosed Heart Failure Patients With Reduced, Mildly Reduced, and Preserved Ejection Fraction. *Am J Cardiol.* 2023;198:72-8. Epub 20230518. doi: 10.1016/j.amjcard.2023.04.035. PubMed PMID: 37209530.
  122. Nixon AC, Bampouras TM, Pendleton N, Woywodt A, Mitra S, Dhaygude A. Frailty and chronic kidney disease: current evidence and continuing uncertainties. *Clin Kidney J.* 2018;11(2):236-45. Epub 20171202. doi: 10.1093/ckj/sfx134. PubMed PMID: 29644065; PubMed Central PMCID: PMC5888002.
  123. Novartis Pharmaceuticals Corporation. Entresto (sacubitril and valsartan) [package insert]. U.S. Food and Drug Administration. Revised 2021 Feb. Available from: [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2021/207620s018lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/207620s018lbl.pdf).
  124. Novo Nordisk Inc. Ozempic (semaglutide) [package insert]. U.S. Food and Drug Administration. Revised 2023 Sep. Available from: [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2023/209637s020s021lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209637s020s021lbl.pdf).
  125. Novo Nordisk Inc. Rybelsus (semaglutide) [package insert]. U.S. Food and Drug Administration. Revised 2023 Jan. Available from: [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2023/213051s012lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213051s012lbl.pdf).
  126. Novo Nordisk Inc. Victoza (liraglutide) [package insert]. U.S. Food and Drug Administration. Revised 2023 Jul. Available from: [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2023/022341s039lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/022341s039lbl.pdf).
  127. Nuffield Department of Population Health Renal Studies Group, SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists' Consortium. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. *Lancet.* 2022;400(10365):1788-801. Epub 20221106. doi: 10.1016/S0140-6736(22)02074-8. PubMed PMID: 36351458; PubMed Central PMCID: PMC7613836.
  128. Ostrominski JW, Thierer J, Claggett BL, Miao ZM, Desai AS, Jhund PS, et al. Cardio-Renal-Metabolic Overlap, Outcomes, and Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction. *JACC Heart Fail.* 2023;11(11):1491-503. Epub 20230524. doi: 10.1016/j.jchf.2023.05.015. PubMed PMID: 37226448.
  129. Parliamentary Office of Science & Technology. Postnote: Drug pricing. Houses of Parliament; 2010 Oct. Report No. 364. Available from: [https://www.parliament.uk/globalassets/documents/post/postpn\\_364\\_Drug\\_Pricing.pdf](https://www.parliament.uk/globalassets/documents/post/postpn_364_Drug_Pricing.pdf).
  130. Peikert A, Goyal P, Vaduganathan M, Claggett BL, Kulac IJ, Miao ZM, et al. Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction According to Polypharmacy Status. *JACC Heart Fail.* 2023;11(10):1380-93. Epub 20230521. doi: 10.1016/j.jchf.2023.05.014. PubMed PMID: 37294244.
  131. Peikert A, Martinez FA, Vaduganathan M, Claggett BL, Kulac IJ, Desai AS, et al. Efficacy and Safety of Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction According to Age: The DELIVER Trial. *Circ Heart Fail.* 2022;15(10):e010080. Epub 20220827. doi: 10.1161/CIRCHEARTFAILURE.122.010080. PubMed PMID: 36029467.

132. Pfizer, Inc. Glucotrol (glipizide) [package insert]. U.S. Food and Drug Administration. Revised 2016. Available from: [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2016/017783s026lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/017783s026lbl.pdf).
133. Qin L, Young R, Darlington O, Song B, McEwan P. PCV17 Matching Adjusted Indirect Comparison between Dapa-HF and Paradigm-HF for the Treatment of Heart Failure with Reduced Ejection Fraction. *Value in Health*. 2020;23(Supplement 2):S489. doi: 10.1016/j.jval.2020.08.508.
134. Race, Ethnicity, & Kidney Disease [Internet]. New York: National Kidney Foundation [cited 2023 Oct 25]. Available from: <https://www.kidney.org/kidney-topics/race-ethnicity-kidney-disease>.
135. Raz I, Mosenzon O, Bonaca MP, Cahn A, Kato ET, Silverman MG, et al. DECLARE-TIMI 58: Participants' baseline characteristics. *Diabetes Obes Metab*. 2018;20(5):1102-10. Epub 20180214. doi: 10.1111/dom.13217. PubMed PMID: 29322605.
136. Rodriguez JE, Campbell KM. Racial and Ethnic Disparities in Prevalence and Care of Patients With Type 2 Diabetes. *Clin Diabetes*. 2017;35(1):66-70. doi: 10.2337/cd15-0048. PubMed PMID: 28144049; PubMed Central PMCID: PMC5241767.
137. Rossing P, Inzucchi SE, Vart P, Jongs N, Docherty KF, Jhund PS, et al. Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials. *Lancet Diabetes Endocrinol*. 2022;10(1):24-34. Epub 20211129. doi: 10.1016/S2213-8587(21)00295-3. PubMed PMID: 34856173.
138. Saeed F, Ladwig SA, Epstein RM, Monk RD, Duberstein PR. Dialysis Regret: Prevalence and Correlates. *Clin J Am Soc Nephrol*. 2020;15(7):957-63. Epub 20200604. doi: 10.2215/CJN.13781119. PubMed PMID: 32499230; PubMed Central PMCID: PMC7341783.
139. Samson SL, Vellanki P, Blonde L, Christofides EA, Galindo RJ, Hirsch IB, et al. American Association of Clinical Endocrinology Consensus Statement: Comprehensive Type 2 Diabetes Management Algorithm - 2023 Update. *Endocr Pract*. 2023;29(5):305-40. doi: 10.1016/j.eprac.2023.02.001. PubMed PMID: 37150579.
140. sanofi-aventis U.S. LLC. Amaryl (glimepiride) [package insert]. U.S. Food and Drug Administration. Revised 2018 Dec. Available from: [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2018/020496s029lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020496s029lbl.pdf).
141. Scheen AJ, Bonnet F. Efficacy and safety profile of SGLT2 inhibitors in the elderly: How is the benefit/risk balance? *Diabetes Metab*. 2023;49(2):101419. Epub 20230111. doi: 10.1016/j.diabet.2023.101419. PubMed PMID: 36640828.
142. Scheen AJ. An update on the safety of SGLT2 inhibitors. *Expert Opin Drug Saf*. 2019;18(4):295-311. Epub 20190416. doi: 10.1080/14740338.2019.1602116. PubMed PMID: 30933547.
143. Scheen AJ. Cardiovascular and renal outcomes with SGLT2 inhibitors: Real-life observational studies in older patients with type 2 diabetes SGLT2 inhibitors in elderly and real life. *Diabet Epidemiol Man*. 2023;10. doi: ARTN 100135 10.1016/j.deman.2023.100135. PubMed PMID: WOS:001136478800001.
144. Sehgal AR, Slutzman JE, Huml AM. Sources of Variation in the Carbon Footprint of Hemodialysis Treatment. *J Am Soc Nephrol*. 2022;33(9):1790-5. Epub 20220602. doi: 10.1681/ASN.2022010086. PubMed PMID: 35654600; PubMed Central PMCID: PMC9529184.
145. Shi Q, Nong K, Vandvik PO, Guyatt GH, Schnell O, Ryden L, et al. Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. *BMJ*. 2023;381:e074068. Epub 20230406. doi: 10.1136/bmj-2022-074068. PubMed PMID: 37024129; PubMed Central PMCID: PMC10077111.



146. Shi SM, Steinberg N, Oh G, Olivieri-Mui B, Sison S, McCarthy EP, et al. Change in a Claims-Based Frailty Index, Mortality, and Health Care Costs in Medicare Beneficiaries. *J Gerontol A Biol Sci Med Sci*. 2023;78(7):1198-203. doi: 10.1093/gerona/glad010. PubMed PMID: 36630699; PubMed Central PMCID: PMC10329229.
147. Shin H, Schneeweiss S, Glynn RJ, Paterno E. Cardiovascular Outcomes in Patients Initiating First-Line Treatment of Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors Versus Metformin: A Cohort Study. *Ann Intern Med*. 2022;175(7):927-37. Epub 20220524. doi: 10.7326/M21-4012. PubMed PMID: 35605236.
148. Shlipak MG, Tummalaipalli SL, Boulware LE, Grams ME, Ix JH, Jha V, et al. The case for early identification and intervention of chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. *Kidney Int*. 2021;99(1):34-47. Epub 20201027. doi: 10.1016/j.kint.2020.10.012. PubMed PMID: 33127436.
149. Sohn M, Dietrich JW, Nauck MA, Lim S. Characteristics predicting the efficacy of SGLT-2 inhibitors versus GLP-1 receptor agonists on major adverse cardiovascular events in type 2 diabetes mellitus: a meta-analysis study. *Cardiovasc Diabetol*. 2023;22(1):153. Epub 20230628. doi: 10.1186/s12933-023-01877-6. PubMed PMID: 37381019; PubMed Central PMCID: PMC10303335.
150. Solomon SD, McMurray JJV, Claggett B, de Boer RA, DeMets D, Hernandez AF, et al. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. *N Engl J Med*. 2022;387(12):1089-98. Epub 20220827. doi: 10.1056/NEJMoa2206286. PubMed PMID: 36027570.
151. Statistics About Diabetes [Internet]. Virginia: American Diabetes Association [cited 2023 Oct 2]. Available from: <https://diabetes.org/about-diabetes/statistics/about-diabetes>.
152. Strain W, Griffiths J. A systematic review and meta-analysis of the impact of GLP-1 receptor agonists and SGLT-2 inhibitors on cardiovascular outcomes in biologically healthy older adults. *British Journal of Diabetes*. 2021;21. doi: 10.15277/bjd.2021.292.
153. Sud M, Tangri N, Pintilie M, Levey AS, Naimark D. Risk of end-stage renal disease and death after cardiovascular events in chronic kidney disease. *Circulation*. 2014;130(6):458-65. Epub 20140604. doi: 10.1161/CIRCULATIONAHA.113.007106. PubMed PMID: 24899688.
154. Takeda Pharmaceuticals. Actos (pioglitazone) [package insert]. U.S. Food and Drug Administration. Revised 2017 Dec. Available from: [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2017/021073s049lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021073s049lbl.pdf).
155. Teo YH, Yoong CSY, Syn NL, Teo YN, Cheong JYA, Lim YC, et al. Comparing the clinical outcomes across different sodium/glucose cotransporter 2 (SGLT2) inhibitors in heart failure patients: a systematic review and network meta-analysis of randomized controlled trials. *Eur J Clin Pharmacol*. 2021;77(10):1453-64. Epub 20210503. doi: 10.1007/s00228-021-03147-4. PubMed PMID: 33942132.
156. The EMPA-KIDNEY Collaborative Group, Herrington WG, Staplin N, Wanner C, Green JB, Hauske SJ, et al. Empagliflozin in Patients with Chronic Kidney Disease. *N Engl J Med*. 2023;388(2):117-27. Epub 20221104. doi: 10.1056/NEJMoa2204233. PubMed PMID: 36331190; PubMed Central PMCID: PMC7614055.
157. TheracosBio. Brenzavvy (bexagliflozin) [package insert]. U.S. Food and Drug Administration. Revised 2023 Sep. Available from: [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2023/214373s001lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/214373s001lbl.pdf).
158. Tilinca MC, Tiuca RA, Tilea I, Varga A. The SGLT-2 Inhibitors in Personalized Therapy of Diabetes Mellitus Patients. *J Pers Med*. 2021;11(12). Epub 20211125. doi: 10.3390/jpm11121249. PubMed PMID: 34945721; PubMed Central PMCID: PMC8708213.

159. Tsapas A, Avgerinos I, Karagiannis T, Malandris K, Manolopoulos A, Andreadis P, et al. Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes: A Systematic Review and Network Meta-analysis. *Ann Intern Med.* 2020;173(4):278-86. Epub 20200630. doi: 10.7326/M20-0864. PubMed PMID: 32598218.
160. Vaduganathan M, Claggett BL, Jhund P, de Boer RA, Hernandez AF, Inzucchi SE, et al. Time to Clinical Benefit of Dapagliflozin in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Secondary Analysis of the DELIVER Randomized Clinical Trial. *JAMA Cardiol.* 2022;7(12):1259-63. doi: 10.1001/jamacardio.2022.3750. PubMed PMID: 36190011; PubMed Central PMCID: PMC9531091.
161. Vaduganathan M, Docherty KF, Claggett BL, Jhund PS, de Boer RA, Hernandez AF, et al. SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials. *Lancet.* 2022;400(10354):757-67. Epub 20220827. doi: 10.1016/S0140-6736(22)01429-5. PubMed PMID: 36041474.
162. Vart P, Butt JH, Jongs N, Schechter M, Chertow GM, Wheeler DC, et al. Efficacy and Safety of Dapagliflozin in Patients With Chronic Kidney Disease Across the Spectrum of Frailty. *J Gerontol A Biol Sci Med Sci.* 2024;79(2). doi: 10.1093/gerona/glad181. PubMed PMID: 37527836; PubMed Central PMCID: PMC10809037.
163. Vart P, Jongs N, Wheeler DC, Heerspink HJL, Langkilde AM, Chertow GM. Effectiveness and Safety of Dapagliflozin for Black vs White Patients With Chronic Kidney Disease in North and South America: A Secondary Analysis of a Randomized Clinical Trial. *JAMA Netw Open.* 2023;6(4):e2310877. Epub 20230403. doi: 10.1001/jamanetworkopen.2023.10877. PubMed PMID: 37103935; PubMed Central PMCID: PMC10140802.
164. Vitale C, Spoletini I, Rosano GM. Frailty in Heart Failure: Implications for Management. *Card Fail Rev.* 2018;4(2):104-6. doi: 10.15420/cfr.2018.22.2. PubMed PMID: 30206485; PubMed Central PMCID: PMC6125710.
165. Weisser B, Predel HG, Gillessen A, Hacke C, Vor dem Esche J, Rippin G, et al. Single Pill Regimen Leads to Better Adherence and Clinical Outcome in Daily Practice in Patients Suffering from Hypertension and/or Dyslipidemia: Results of a Meta-Analysis. *High Blood Press Cardiovasc Prev.* 2020;27(2):157-64. Epub 20200326. doi: 10.1007/s40292-020-00370-5. PubMed PMID: 32219670; PubMed Central PMCID: PMC7160084.
166. Wheeler DC, Stefansson BV, Jongs N, Chertow GM, Greene T, Hou FF, et al. Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial. *Lancet Diabetes Endocrinol.* 2021;9(1):22-31. doi: 10.1016/S2213-8587(20)30369-7. PubMed PMID: 33338413.
167. Wilding J, Fernando K, Milne N, Evans M, Ali A, Bain S, et al. SGLT2 Inhibitors in Type 2 Diabetes Management: Key Evidence and Implications for Clinical Practice. *Diabetes Ther.* 2018;9(5):1757-73. Epub 20180723. doi: 10.1007/s13300-018-0471-8. PubMed PMID: 30039249; PubMed Central PMCID: PMC6167302.
168. Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. *N Engl J Med.* 2019;380(4):347-57. Epub 20181110. doi: 10.1056/NEJMoa1812389. PubMed PMID: 30415602.
169. Xie Y, Bowe B, Xian H, Loux T, McGill JB, Al-Aly Z. Comparative effectiveness of SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, and sulfonylureas on risk of major adverse cardiovascular events: emulation of a randomised target trial using electronic health records. *Lancet Diabetes Endocrinol.* 2023;11(9):644-56. Epub 20230724. doi: 10.1016/S2213-8587(23)00171-7. PubMed PMID: 37499675.

170. Yamada T, Wakabayashi M, Bhalla A, Chopra N, Miyashita H, Mikami T, et al. Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysis. *Cardiovasc Diabetol*. 2021;20(1):14. Epub 20210107. doi: 10.1186/s12933-020-01197-z. PubMed PMID: 33413348; PubMed Central PMCID: PMC7792332.
171. Zaccardi F, Webb DR, Htike ZZ, Youssef D, Khunti K, Davies MJ. Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis. *Diabetes Obes Metab*. 2016;18(8):783-94. Epub 20160513. doi: 10.1111/dom.12670. PubMed PMID: 27059700.
172. Zannad F, Rossignol P. Cardiorenal Syndrome Revisited. *Circulation*. 2018;138(9):929-44. doi: 10.1161/CIRCULATIONAHA.117.028814. PubMed PMID: 30354446.
173. Zareini B, Blanche P, D'Souza M, Elmegaard Malik M, Norgaard CH, Selmer C, et al. Type 2 Diabetes Mellitus and Impact of Heart Failure on Prognosis Compared to Other Cardiovascular Diseases: A Nationwide Study. *Circ Cardiovasc Qual Outcomes*. 2020;13(7):e006260. Epub 20200623. doi: 10.1161/CIRCOUTCOMES.119.006260. PubMed PMID: 32571092.
174. Zhang Y, Jiang L, Wang J, Wang T, Chien C, Huang W, et al. Network meta-analysis on the effects of finerenone versus SGLT2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus and chronic kidney disease. *Cardiovasc Diabetol*. 2022;21(1):232. Epub 20221105. doi: 10.1186/s12933-022-01676-5. PubMed PMID: 36335326; PubMed Central PMCID: PMC9637313.

## Redacted Negotiation Meeting Summaries for Farxiga

Below are summaries of the negotiation meetings between CMS and the Primary Manufacturer, which include redacted information regarding the negotiation meetings and exchange of offers and counteroffers in the meetings.



---

**SUBJECT:** Meeting Summary from Negotiation Meeting between the Centers for Medicare & Medicaid Services (CMS) and AstraZeneca AB regarding Farxiga on April 23, 2024

**Background:** Sections 11001 and 11002 of the Inflation Reduction Act of 2022 (IRA) (P.L. 117-169), signed into law on August 16, 2022, established the Medicare Drug Price Negotiation Program (hereafter the “Negotiation Program”) to enable the Centers for Medicare & Medicaid Services (CMS) to negotiate maximum fair prices (MFPs) with willing manufacturers for certain high expenditure, single source drugs and biological products. AstraZeneca AB (hereafter “the Primary Manufacturer”) chose to enter into an agreement to participate in the Negotiation Program for Farxiga (hereafter “the Selected Drug”).

In accordance with revised guidance and in the course of negotiation for the Selected Drug, CMS invited the Primary Manufacturer to a negotiation meeting when rejecting the Primary Manufacturer’s counteroffer, and the Primary Manufacturer accepted CMS’ invitation. CMS shared a proposed meeting agenda with the Primary Manufacturer approximately two weeks before the meeting. The Primary Manufacturer had the opportunity to request additions or edits to the agenda at least one week ahead of the meeting. This document includes a summary prepared by CMS of the first negotiation meeting, which was held on April 23, 2024 between 12:30 PM ET and 3:00 PM ET.

**CMS Attendees:**

1. Bansri Desai, Division of Rebate Agreements and Drug Price Negotiation
2. Scott Falin, Representative from the Office of the General Counsel
3. Dan Heider, Director, Division of Rebate Agreements and Drug Price Negotiation
4. Tina Li, Medicare Drug Rebate and Negotiations Group
5. Corey Rosenberg, Deputy Director, Division of Rebate Agreements and Drug Price Negotiation
6. Lara Strawbridge, Deputy Director of Policy, Medicare Drug Rebate and Negotiations Group

**Primary Manufacturer Attendees:**

1. Sarah Arbes, Head of Corporate Affairs, U.S. Federal Government
2. Domenick Fanelli, Executive Director, Portfolio Contract Strategy
3. Susan Farkas, Executive Director, Payer Team
4. Rod Lauzon, Executive Director Contract Operations
5. Paul Miller, Head Clinical Value & Outcomes
6. DC Moxey, CVRM & Market Access Legal Counsel

**Topics:** The discussion focused on topics outlined in the final agenda for the meeting, which was as follows:<sup>1</sup>


- Introductions and meeting reminders
- Discussion of initial offer and any questions from the Primary Manufacturer
- Discussion of counteroffer and any questions from CMS
- Any other considerations that CMS and the Primary Manufacturer would like to discuss

---

<sup>1</sup> Note: This agenda may be inclusive of topics proposed by the Primary Manufacturer.

- Next steps

**Offers/Counteroffers Exchanged:**





---

**SUBJECT:** Meeting Summary from Negotiation Meeting between the Centers for Medicare & Medicaid Services (CMS) and AstraZeneca AB regarding Farxiga on May 22, 2024

**Background:** Sections 11001 and 11002 of the Inflation Reduction Act of 2022 (IRA) (P.L. 117-169), signed into law on August 16, 2022, established the Medicare Drug Price Negotiation Program (hereafter the “Negotiation Program”) to enable the Centers for Medicare & Medicaid Services (CMS) to negotiate maximum fair prices (MFPs) with willing manufacturers for certain high expenditure, single source drugs and biological products. AstraZeneca AB (hereafter “the Primary Manufacturer”) chose to enter into an agreement to participate in the Negotiation Program for Farxiga (hereafter “the Selected Drug”).

In accordance with revised guidance and in the course of negotiation for the Selected Drug, because CMS and the Primary Manufacturer did not reach agreement on an MFP in the first negotiation meeting held on April 23, 2024, each party had the opportunity to request one additional negotiation meeting, resulting in a maximum of three meetings. The Primary Manufacturer requested a second negotiation meeting and CMS accepted the invitation. CMS shared a proposed meeting agenda with the Primary Manufacturer approximately two weeks before the meeting. The Primary Manufacturer had the opportunity to request additions or edits to the agenda at least one week ahead of the meeting. This document includes a summary prepared by CMS of the second negotiation meeting, which was held on May 22, 2024 between 10:00 AM ET and 12:30 PM ET.

**CMS Attendees:**

1. Bansri Desai, Division of Rebate Agreements and Drug Price Negotiation
2. Scott Falin, Representative from the Office of the General Counsel
3. Dan Heider, Director, Division of Rebate Agreements and Drug Price Negotiation
4. Katherine Kehres, Division of Rebate Agreements and Drug Price Negotiation
5. Tina Li, Medicare Drug Rebate and Negotiations Group
6. Lara Strawbridge, Deputy Director of Policy, Medicare Drug Rebate and Negotiations Group

**Primary Manufacturer Attendees:**

1. Sarah Arbes, Head of Corporate Affairs, U.S. Federal Government
2. Domenick Fanelli, Executive Director, Portfolio Contract Strategy
3. Susan Farkas, Executive Director, Payer Team
4. Rod Lauzon, Executive Director Contract Operations
5. Paul Miller, Head Clinical Value & Outcomes
6. DC Moxey, CVRM & Market Access Legal Counsel

**Topics:** The discussion focused on topics outlined in the final agenda for the meeting, which was as follows:<sup>1</sup>

- Introductions and meeting reminders
- Discussion of Farxiga utilization trends across indications
- Any additional information from Primary Manufacturer on medical cost offset data


---

<sup>1</sup> Note: This agenda may be inclusive of topics proposed by the Primary Manufacturer



- Any additional information from Primary Manufacturer on the impact of previously discussed access concerns
- Any other considerations that CMS or the Primary Manufacturer would like to discuss
- Next steps

**Offers/Counteroffers Exchanged:**





---

**SUBJECT:** Meeting Summary from Negotiation Meeting between the Centers for Medicare & Medicaid Services (CMS) and AstraZeneca AB regarding Farxiga on June 28, 2024

**Background:** Sections 11001 and 11002 of the Inflation Reduction Act of 2022 (IRA) (P.L. 117-169), signed into law on August 16, 2022, established the Medicare Drug Price Negotiation Program (hereafter the “Negotiation Program”) to enable the Centers for Medicare & Medicaid Services (CMS) to negotiate maximum fair prices (MFPs) with willing manufacturers for certain high expenditure, single source drugs and biological products. AstraZeneca AB (hereafter “the Primary Manufacturer”) chose to enter into an agreement to participate in the Negotiation Program for Farxiga (hereafter “the Selected Drug”).

In accordance with revised guidance and in the course of negotiation for the Selected Drug, because CMS and the Primary Manufacturer did not reach agreement on an MFP in the second negotiation meeting which was requested by the Primary Manufacturer and held on May 22, 2024, CMS had the opportunity to request one additional negotiation meeting, resulting in a maximum of three meetings. CMS requested a third negotiation meeting and the Primary Manufacturer accepted the invitation. CMS shared a proposed meeting agenda with the Primary Manufacturer approximately two weeks before the meeting. The Primary Manufacturer had the opportunity to request additions or edits to the agenda at least one week ahead of the meeting. This document includes a summary prepared by CMS of the third negotiation meeting, which was held on June 28, 2024 between 9:00 AM ET and 11:30 AM ET.

**CMS Attendees:**

1. Bansri Desai, Division of Rebate Agreements and Drug Price Negotiation
2. Scott Falin, Representative from the Office of the General Counsel (virtual attendance)
3. Dan Heider, Director, Division of Rebate Agreements and Drug Price Negotiation
4. Tina Li, Medicare Drug Rebate and Negotiations Group
5. Corey Rosenberg, Deputy Director, Division of Rebate Agreements and Drug Price Negotiation
6. Lara Strawbridge, Deputy Director of Policy, Medicare Drug Rebate and Negotiations Group

**Primary Manufacturer Attendees:**

1. Sarah Arbes, Head of Corporate Affairs, U.S. Federal Government
2. Domenick Fanelli, Executive Director, Portfolio Contract Strategy
3. Susan Farkas, Executive Director, Payer Team
4. Rod Lauzon, Executive Director Contract Operations
5. Paul Miller, Head Clinical Value & Outcomes
6. DC Moxey, CVRM & Market Access Legal Counsel

**Topics:** The discussion focused on topics outlined in the final agenda for the meeting, which was as follows:<sup>1</sup>

- Introductions and meeting reminders
- Clarification on the process to reach an agreed price

---

<sup>1</sup> Note: This agenda may be inclusive of topics proposed by the Primary Manufacturer.

- Review of timeline
  - Allowable communication post-3rd negotiation meeting
  - Formal documentation process / contract sign-off
  - CMS communication plan of MFP
- Revised offer/counteroffer price discussion
- Any other considerations that CMS and the Primary Manufacturer would like to discuss
- Next steps

**Offers/Counteroffers Exchanged:**

